Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-08-28

FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Briviact (brivaracetam) submitted by UCB, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Briviact (brivaracetam)

Snippet

SUPPL AP for BRIVIACT (BRIVARACETAM)